Moderna, Inc.
Moderna, Inc.
Your view on MRNA
Overview
What the company does, where it operates, and who runs it.
About Moderna, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Stéphane Bancel
- Headquarters
- 200 Technology Square, Cambridge, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Stéphane Bancel
- Headquarters
- 200 Technology Square, Cambridge, MA, US
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.
Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics.
It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Moderna, Inc. from FRC's valuation model, read against the market price. MRNA last traded at $215.27; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Moderna, Inc.. Starting points for Moderna, Inc.: EPS -$6.96, beta 0.90 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Moderna, Inc.. Moderna, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Moderna, Inc.. Trailing twelve-month EPS for Moderna, Inc. stands at -$6.96. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$122.73
average of 15 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy2
- Hold9
- Sell5
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$2.07 | -$1.76 | -$7.46 | -$4.33 |
| Low estimate | -$3.84 | -$2.01 | -$9.55 | -$6.96 |
| High estimate | -$1.36 | -$1.59 | -$2.94 | -$2.49 |
| No. of analysts | 11 | 5 | 16 | 17 |
| Year-ago EPS | -$2.11 | -$3.40 | -$7.261 | — |
| Growth | +2.0% | +48.4% | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $529.71M | $302.19M | $2.31B | $2.65B |
| Low estimate | $269.80M | $123.44M | $2.14B | $2.11B |
| High estimate | $678.72M | $480.95M | $2.52B | $3.43B |
| No. of analysts | 9 | 3 | 14 | 17 |
| Year-ago revenue | $678.00M | $389.00M | $1.94B | — |
| Growth | -21.9% | -22.3% | +18.7% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0, Investing; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Moderna, Inc.. Moderna, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ARCTArcturus Therapeutics Holdings Inc.Biotechnology$240M
- BNTXBioNTech SEBiotechnology$21.1B
- GSKGSK plcDrug Manufacturers - General$101.3B
- INOInovio Pharmaceuticals, Inc.Biotechnology$97M
- NVAXNovavax, Inc.Biotechnology$1.3B
- OGENOragenics, Inc.Biotechnology$893,367
- PCVXVaxcyte, Inc.Biotechnology$9.8B
- PFEPfizer Inc.Drug Manufacturers - General$164.5B
More Biotechnology companies
- MIRMMirum Pharmaceuticals, Inc.NASDAQ$6.0B
- MISTMilestone Pharmaceuticals Inc.NASDAQ$45M
- MLECMoolec Science S.A.NASDAQ$617,200
- MLECWMoolec Science S.A.NASDAQ$76,243
- MLLCFMolecular Partners AGOTC$131M
- MLTXMoonLake ImmunotherapeuticsNASDAQ$998M
- MLYSMineralys Therapeutics, Inc.NASDAQ$1.3B
- MMIRFMedMira Inc.OTC$9M
- MNKDMannKind CorporationNASDAQ$1.3B
- MNOVMediciNova, Inc.NASDAQ$69M
- MNPRMonopar Therapeutics Inc.NASDAQ$488M
- MOLNMolecular Partners AGNASDAQ$103M
ETFs holding Moderna, Inc.
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.13%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.11%
- QQQInvesco QQQ Trust, Series 1$446.1B in assets0.39%
- IVViShares Core SP 500 ETF$852.9B in assets0.12%
- IDNAiShares Genomics Immunology and Healthcare ETF$352M in assets13.13%
- BBHVanEck Biotech ETF$536M in assets6.41%
- SPHBInvesco S&P 500 High Beta ETF$782M in assets3.41%
- XBIState Street SPDR S&P Biotech ETF$10.0B in assets2.37%
Largest holders first, then the funds most concentrated in MRNA.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Moderna, Inc., and how their positions are changing. At a $87.10B market value, institutional positions materially move Moderna, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Moderna, Inc. executives and directors. Shares of Moderna, Inc. have traded between $23.04 and $48.92 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Moderna, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Moderna, Inc.. Coverage tracks Moderna, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Moderna, Inc.